Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
D-dimer is a specific fibrin degradation product formed when cross-linked fibrin clots are broken down by plasmin during the process of fibrinolysis. It is a small protein fragment present in the blood only when acute or chronic activation of coagulation and fibrinolysis has occurred, such as in venous thromboembolism, disseminated intravascular coagulation, or major inflammatory states[2][3][6]. D-dimer is composed of two D fragments of fibrin, joined by a cross-link, and is detected in plasma when the coagulation cascade results in the formation of cross-linked fibrin, and subsequent fibrinolysis occurs[1][3][4]. Measurement of D-dimer in blood is widely used as a **diagnostic biomarker** to exclude or monitor thrombotic events, but it is not itself a molecular drug target, receptor, or enzyme. Because D-dimer is not a receptor, enzyme, transporter, or mediator of biological effects, but rather an **excreted marker of clot breakdown**, it is not subject to pharmacologic modulation or direct drug binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibrin degradation product D-dimer (D-dimer).